On September 4, 2025, Opus Genetics, Inc. announced that the first patient has been dosed in LYNX-3, its pivotal Phase 3 clinical trial. This trial is evaluating Phentolamine Ophthalmic Solution 0.75% for treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
LYNX-3 is the second Phase 3 trial for this indication, which has Fast Track designation from the U.S. Food and Drug Administration (FDA) and is being conducted under a Special Protocol Assessment (SPA). This follows positive topline results from the first Phase 3 trial, LYNX-2, announced in June 2025.
Night-vision disturbances, including glare, halos, and starbursts, are common after keratorefractive procedures and currently lack FDA-approved treatments. The LYNX-3 study aims to further evaluate if Phentolamine Ophthalmic Solution 0.75% can meaningfully improve functional dim light vision and reduce patient-reported visual disturbances.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.